User profiles for Peter J. Greasley
Peter GreasleyEarly Clinical Development, AstraZeneca Verified email at astrazeneca.com Cited by 8494 |
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
The effect of a sodium glucose cotransporter 2 inhibitor (SGLT2i) in reducing heart failure
hospitalization in the EMPA‐REG OUTCOMES trial has raised the possibility of using these …
hospitalization in the EMPA‐REG OUTCOMES trial has raised the possibility of using these …
Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes
…, M Sjöstrand, SD Solomon, P Johanson, PJ Greasley… - Jama, 2020 - jamanetwork.com
Importance Additional treatments are needed for heart failure with reduced ejection fraction (HFrEF).
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …
The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo
…, SA Ridge, K Mackie, PJ Greasley… - Proceedings of the …, 2009 - National Acad Sciences
GPR55 is a G protein-coupled receptor recently shown to be activated by certain cannabinoids
and by lysophosphatidylinositol (LPI). However, the physiological role of GPR55 remains …
and by lysophosphatidylinositol (LPI). However, the physiological role of GPR55 remains …
Dapagliflozin and diuretic use in patients with heart failure and reduced ejection fraction in DAPA-HF
…, DL DeMets, KF Docherty, A Dukát, PJ Greasley… - Circulation, 2020 - Am Heart Assoc
Background: In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the risk of …
Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial
…, D Cattran, AHA Gafor, PJ Greasley… - The lancet Diabetes & …, 2020 - thelancet.com
Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …
[HTML][HTML] Identification and characterisation of a novel splice variant of the human CB1 receptor
…, S Hjorth, T Elebring, S Sjögren, PJ Greasley - FEBS letters, 2005 - Elsevier
Cannabinoid ligands are implicated in many physiological processes and to date two
receptors have been identified. However, a growing body of evidence exists that suggests the …
receptors have been identified. However, a growing body of evidence exists that suggests the …
Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function
S Petrykiv, CD Sjöström, PJ Greasley, J Xu… - Clinical Journal of the …, 2017 - journals.lww.com
Results Compared with placebo, reductions in HbA1c with dapagliflozin were 0.6%, 0.5%,
and 0.3%, respectively, for each consecutive lower eGFR subgroup (P value interaction< …
and 0.3%, respectively, for each consecutive lower eGFR subgroup (P value interaction< …
Natriuretic effect of two weeks of dapagliflozin treatment in patients with type 2 diabetes and preserved kidney function during standardized sodium intake: results of …
…, MJB van Baar, AC Hesp, PJ Greasley… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for heart
failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and plasma …
failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and plasma …
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
…, D O'Neill, A Plain, PJ Greasley… - Science translational …, 2018 - science.org
Hyperphosphatemia is common in patients with chronic kidney disease and is increasingly
associated with poor clinical outcomes. Current management of hyperphosphatemia with …
associated with poor clinical outcomes. Current management of hyperphosphatemia with …
Effects of the sodium‐glucose co‐transporter‐2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes
CCJ Dekkers, CD Sjöström, PJ Greasley… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aims To compare the effects of the sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor
dapagliflozin on estimated (ePV) and measured plasma volume (mPV) and to characterize the …
dapagliflozin on estimated (ePV) and measured plasma volume (mPV) and to characterize the …